These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 6678866)
1. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. Knight WA; Von Hoff DD; Neidhart JA; Tranum BL; Fabian C; Jones SE Invest New Drugs; 1983; 1(2):181-4. PubMed ID: 6678866 [TBL] [Abstract][Full Text] [Related]
2. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas]. Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026 [TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer. Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma. Arseneau JC; Schoenfeld DA; Borden EC Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041 [TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. Coleman RE; Maisey MN; Knight RK; Rubens RD Eur J Cancer Clin Oncol; 1984 Jun; 20(6):771-6. PubMed ID: 6540179 [TBL] [Abstract][Full Text] [Related]
6. [Phase II study of mitoxantrone in advanced breast cancer]. Ogawa M; Kubo K; Tominaga T; Nomura Y; Ota K; Yoshida M; Taguchi T; Hoshino A Gan To Kagaku Ryoho; 1986 May; 13(5):1980-4. PubMed ID: 3707156 [TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot. Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195 [TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report. Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP Am J Clin Oncol; 1983 Aug; 6(4):473-6. PubMed ID: 6869318 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group study. Ravdin PM; Green S; Doroshow JH; Martino S Invest New Drugs; 1994; 12(4):333-6. PubMed ID: 7775136 [TBL] [Abstract][Full Text] [Related]
12. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006 [TBL] [Abstract][Full Text] [Related]
13. First-line mitoxantrone chemotherapy for advanced breast cancer. Wilson KS; Paterson AH Cancer Treat Rep; 1986 Aug; 70(8):1021-2. PubMed ID: 3731148 [TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone as a first-line treatment of advanced breast cancer. Landys K; Borgstrom S; Andersson T; Noppa H Invest New Drugs; 1985; 3(2):133-7. PubMed ID: 4019117 [TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT; Smyth JF Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1141-6. PubMed ID: 6541135 [TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study. Mouridsen HT; Rose C; Nooy MA; van Oosterom AT Cancer Treat Rev; 1983 Dec; 10 Suppl B():47-52. PubMed ID: 6661734 [TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Osborne CK; Drelichman A; Von Hoff DD; Crawford ED Cancer Treat Rep; 1983 Dec; 67(12):1133-5. PubMed ID: 6652630 [TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours. Stuart-Harris RC; Smith IE Cancer Chemother Pharmacol; 1982; 8(2):179-82. PubMed ID: 7105382 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Cowan JD; Osborne CK; Neidhart JA; Von Hoff DD; Constanzi JJ; Vaughn CB Invest New Drugs; 1985; 3(2):149-52. PubMed ID: 3894277 [TBL] [Abstract][Full Text] [Related]
20. High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. Leiby JM; Unverfurth DV; Neidhart JA Cancer Treat Rep; 1986 Jul; 70(7):899-901. PubMed ID: 3719583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]